Tomudex contains the active substance raltitrexed. Raltitrexed is part of a group of drugs known as anti-metabolites. Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA so they can grow and form more cells.

Tomudex is used to treat cancer which affects the colon and rectum (parts of your ‘bowel’ or ‘gut’) and is often given with other drugs. It works by killing cells within your body which cause certain types of cancer. Tomudex is intended for use in adults only.

A doctor or nurse will give you Tomudex through a drip in your vein (intravenous infusion [IV]) over 15 minutes. This medicine can only be obtained with a prescription and is administered in a hospital environment under the supervision of a physician who is experienced in cancer chemotherapy.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Tomudex these can be found at the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.